title: Second primary head and neck squamous cell cancers with aggressive behavior in patients with chronic myeloid leukaemia.
abstract: Patients with chronic myeloid leukaemia (CML) are at considerable risk of developing second primary neoplasms. However, mucosal squamous cell cancers (SCCs) of the head and neck have not been reported. We review the data of 7 patients with mucosal SCC of the head and neck that presented as metachronous second primary tumours in patients with CML. All 7 patients were men (median age 48 years, range 31-67) (site:oral cavity n=6, hypopharynx n=1). The median interval between diagnosis of CML and head neck cancer was 6 years (range 2-15). Treatment was curative in 4 and palliative in 3. At median follow up of 14 months (range 2-44), 3 patients had died of head and neck cancer, 1 of CML, and 3 were alive and free of disease. Mucosal cancers of the head and neck can occur in long-term survivors of CML. They are aggressive and tend to recur.
authors: Department of Radiation Oncology, Tata Memorial Hospital, Ernest Borges Marg, Parel, Mumbai 400012, India. ashwininb@yahoo.com
authors: Ashwini
authors: A
authors: Budrukkar
authors: Sidramesh
authors: S
authors: Muttagi
authors: Tanveer
authors: T
authors: Shahid
authors: Pankaj
authors: P
authors: Chatturvedi
authors: Shripad
authors: S
authors: Banavali
authors: Sarbani Ghosh
authors: SG
authors: Laskar
authors: Vedang
authors: V
authors: Murthy
authors: Anil
authors: A
authors: D'Cruz
authors: Jai Prakash
authors: JP
authors: Agarwal
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D002294:Carcinoma, Squamous Cell / Q000473:pathology*; D002423:Cause of Death; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D005887:Gingival Neoplasms / Q000473:pathology; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007012:Hypopharyngeal Neoplasms / Q000473:pathology; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000473:pathology*; D016609:Neoplasms, Second Primary / Q000473:pathology*; D010166:Palliative Care; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use; D013997:Time Factors; D014062:Tongue Neoplasms / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D006918:Hydroxyurea